Wu et al. first proposed individual differences in the abundance of EGFR mutations in NSCLC by direct sequencing and using the amplification refractory mutation system (ARMS), which indicated that patients with high mutation abundance treated with EGFR-TKIs had significantly longer PFS than those with low mutation abundance [18]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.